Tirzepatide's effects on obesity-related heart failure with preserved pumping function differ by sex

Tirzepatide decreased the risk of cardiovascular death or worsening heart failure in patients with obesity-related heart failure with preserved ejection fraction.

• The SUMMIT trial evaluated the effects of tirzepatide on heart failure outcomes.
• Patients with obesity-related heart failure with preserved ejection fraction were the focus of the study.
• Sexual dimorphisms may affect how body fat relates to the disease and treatment response.

Simplified